Ewing sarcoma
Drug research and approvals for ewing sarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 58 studies of ewing sarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 7 open orphan designations naming it.
- Recruiting worldwide: 58
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 58 recruiting on ClinicalTrials.gov ↗- Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's LymphomaNCT07514819 · Not applicable · St. Jude Children's Research Hospital · starts Aug 20, 2026
- Eflornithine (DFMO) for Ewing Sarcoma and OsteosarcomaNCT07321912 · Phase 2 · Milton S. Hershey Medical Center · starts Jun 5, 2026
- Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasNCT06465199 · Phase 1 / Phase 2 · Milton S. Hershey Medical Center · starts May 13, 2026
- Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid TumorsNCT07628634 · Early Phase 1 · University of California, Irvine · starts May 1, 2026
- Identification of Circulating Biomarkers Associated With Extracellular Vesicles in SarcomasNCT07685405 · Not reported · Istituto Ortopedico Rizzoli · starts Apr 15, 2026
- Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)NCT07297979 · Phase 1 · Amgen · starts Apr 8, 2026
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsNCT06625190 · Phase 1 / Phase 2 · University of Florida · starts Feb 11, 2026
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesNCT07194044 · Phase 1 · H. Lee Moffitt Cancer Center and Research Institute · starts Feb 5, 2026
- Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)NCT07172958 · Phase 1 · Children's National Research Institute · starts Jan 27, 2026
- Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory…NCT07222735 · Phase 1 · St. Jude Children's Research Hospital · starts Jan 21, 2026
Drug Pipeline
12 in phase 3, 13 in phase 2, 16 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Irinotecan
- Phase 3 DNA topoisomerase I inhibitor
- Temozolomide
- Phase 3 DNA inhibitor
- Vincristine
- Phase 3 Tubulin inhibitor
- Cyclophosphamide anhydrous
- Phase 3 DNA inhibitor
- Busulfan
- Phase 3 DNA inhibitor
- Doxorubicin
- Phase 3 DNA topoisomerase II alpha inhibitor
- Ifosfamide
- Phase 3 DNA inhibitor
- Modafinil
- Phase 3 Dopamine transporter inhibitor
- (r)-melphalan
- Phase 3
- Treosulfan
- Phase 3 DNA cross-linking agent
- Zoledronic acid anhydrous
- Phase 3 Farnesyl diphosphate synthase inhibitor
- Dactinomycin
- Phase 3 DNA inhibitor
- Filgrastim
- Phase 2 Granulocyte colony stimulating factor receptor agonist
- Dexrazoxane
- Phase 2 Iron sequestering agent
- Topotecan
- Phase 2 DNA topoisomerase I inhibitor
- Olaparib
- Phase 2 PARP 1, 2 and 3 inhibitor
- Docetaxel anhydrous
- Phase 2 Tubulin inhibitor
- Naxitamab
- Phase 2 Disialoganglioside GD2 binding agent
- 2-MERCAPTOETHANESULFONIC acid
- Phase 2 Unknown
- Gemcitabine
- Phase 2 Ribonucleoside-diphosphate reductase RR1 inhibitor
- Indinavir anhydrous
- Phase 2 Human immunodeficiency virus type 1 protease inhibitor
- Palbociclib
- Phase 2 CDK6/cyclin D1 inhibitor
- Linsitinib
- Phase 2 Insulin-like growth factor I receptor inhibitor
- Ganitumab
- Phase 2 Insulin-like growth factor I receptor antagonist
- Figitumumab
- Phase 1 Insulin-like growth factor I receptor antagonist
- Lurbinectedin
- Phase 1 DNA negative modulator
- Fludarabine
- Phase 1
- Interferon GAMMA-1B
- Phase 1 Interferon gamma receptor agonist
- Plicamycin
- Phase 1 DNA inhibitor
Showing the 30 furthest along of 41 in trials.
How Its Trials Ended
264 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 57 whose ending is known, 18% met their primary endpoint, 16% missed it and 67% stopped early.
- Completed, result not reported10741%
- Ongoing8331%
- Stopped: other or unclear197%
- Status unknown176%
- Met its primary endpoint104%
- Stopped: enrollment or feasibility104%
- Missed its primary endpoint93%
- Stopped: sponsor or business decision52%
- Stopped: lack of efficacy31%
- Stopped: funding10%
FDA Orphan Designations
Approved first, then open designations, newest first| Apr 25, 2025 | Dinutuximab betaTreatment of Ewing sarcoma | Recordati Rare Diseases Inc. | Designated |
| Oct 22, 2024 | Small molecule RBM39-degraderTreatment of Ewing sarcoma | SEED Therapeutics Inc. | Designated |
| Jul 9, 2024 | PadnarsertibTreatment of Ewing sarcoma | Karyopharm Therapeutics Inc. | Designated |
| Jan 5, 2021 | Cu-64 anti CD99Diagnostic for the clinical management of Ewing Sarcoma | Advanced Imaging Projects, LLC | Designated |
| Jul 7, 2020 | A novel humanized bispecific XmAb T cell recruiting…Treatment of Ewing Sarcoma | Amgen, Inc. | Designated |
| Jun 30, 2016 | Small molecule Ewing Sarcoma breakpoint region 1/Friend…Treatment of Ewing sarcoma | Georgetown University | Designated |
| Jul 7, 2015 | ANA-conjugated dactunomycin nanoemulsionTreatment of Ewing sarcoma | NanoSmart Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA